user

Clinical Importance of estrogen reactivity in Hormone Receptor Positive HER2-Negative Breast Cancer

被引：0
|
作者：
Takeshita, Takashi [1 ]
Iwase, Hirotaka [1 ]
Takabe, Kazuaki [2 ]
机构：
[1] Kumamoto City Hosp, Kumamoto, Japan
[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1185
引用
收藏
页码：597 / 597
页数：1
相关论文
共 50 条
  • [11] Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
    Kubo, Makoto
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [12] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [13] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [14] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [15] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [16] Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer
    Lopez, M.
    Di Lauro, L.
    Viola, G.
    Foggi, P.
    Conti, F.
    Corsetti, S.
    Sergi, D.
    Botti, C.
    Di Filippo, F.
    Vici, P.
    CLINICA TERAPEUTICA, 2009, 160 (06): : 481 - 488
  • [17] The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer
    Kristin E. Rojas
    Donna-Marie Manasseh
    Mary Rojas
    Andrea Mattocks
    Leah Portnow
    Sarah Kantharia
    Natalie Zelenko
    Christina Giuliano
    Patrick I. Borgen
    Breast Cancer Research and Treatment, 2020, 182 : 79 - 83
  • [18] The Evolving Use of SERDs in Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeselsohn, Rinath M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 428 - 431
  • [19] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    I. Nederlof
    S. Hajizadeh
    F. Sobhani
    S. E. A. Raza
    K. AbdulJabbar
    R. Harkes
    M. J. van de Vijver
    R. Salgado
    C. Desmedt
    M. Kok
    Y. Yuan
    H. M. Horlings
    npj Breast Cancer, 8
  • [20] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    Nederlof, I
    Hajizadeh, S.
    Sobhani, F.
    Raza, S. E. A.
    AbdulJabbar, K.
    Harkes, R.
    van de Vijver, M. J.
    Salgado, R.
    Desmedt, C.
    Kok, M.
    Yuan, Y.
    Horlings, H. M.
    NPJ BREAST CANCER, 2022, 8 (01)
12345